Nkarta (NKTX)
Develops NKX019-led CAR NK therapies for B-cell autoimmune diseases.
Something off on this page? Send us feedback.
Develops pre-commercial, donor-derived CAR NK cell therapies for autoimmune disease, with NKX019 as the lead program. The business has one reportable segment, no approved products or product-sales revenue, and depends on clinical data, enrollment, manufacturing execution, regulatory approval, capital access, and competition from cell-therapy and immunology approaches.
Develops engineered natural killer cell therapies from healthy-donor cells, with NKX019 as the current lead program. The platform uses CD19-directed CAR NK cells and cryopreserved, off-the-shelf manufacturing for B-cell autoimmune diseases.
Clinical work centers on Ntrust-1 and Ntrust-2, plus investigator-sponsored NKX019 studies in systemic lupus erythematosus and myasthenia gravis. Earlier oncology studies for NKX019 and NKX101 closed enrollment and were deprioritized.
Operates as a pre-commercial biotech from South San Francisco with one reportable segment and no approved products or product-sales revenue. The business depends on patient enrollment, clinical data, cell-therapy manufacturing, regulatory approval, capital access, and competition from other cell-therapy and immunology approaches.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jun 23, 2026 | Cowen & Co. | Initiate | Rating: — | |
| May 18, 2026 | Evercore ISI | Target | Target: — | Target: $9 |
| May 15, 2025 | William Blair | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $182.8M · Total debt $73.5M · Total assets $337.6M · Shareholders' equity $247.7M
- Revenue
- $0
- Operating income
- −$43.1M
- Net income
- −$40.4M
No dividends on record.
| Institutions | ≈ 82.90% | 59.37M shares | |
|---|---|---|---|
| 141 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.67% | 1.19M shares | |
| 7 holders · as of Jun 22, 2026 | |||
| Other | ≈ 15.43% | 11.06M shares | |
| remainder | |||
71.62M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Ra Capital Management, L.P.Institution | 15.09% | 10.81M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.80% | 6.30M | as of Jun 30, 2026 |
Nea Management Company, LLCInstitution | 4.98% | 3.57M | as of Jun 30, 2026 |
Samsara Biocapital, LLCInstitution | 4.90% | 3.51M | as of Jun 30, 2026 |
Sr One Capital Management, LPInstitution | 4.65% | 3.33M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 18, 2026 | Paul J. Hastings | director, officer: Chief Executive Officer | −1,776 | $2.71 |
| Jan 15, 2026 | Nadir Mahmood | officer: President | −5,649 | $2.07 |
| Jan 15, 2026 | Paul J. Hastings | director, officer: Chief Executive Officer | −26,046 | $2.07 |
- Kyverna Therapeutics
Autologous CD19 CAR-T immune-reset peer
- Cabaletta Bio
CD19 CAR-T RESET trials across core autoimmune indications
- Bristol-Myers Squibb
Scaled CD19 CAR-T autoimmune franchise with Phase 2 reach
- Fate
Off-the-shelf iPSC CD19 CAR-T for autoimmune disease
- Sana Biotechnology
Hypoimmune allogeneic CD19 CAR-T in lupus and AAV
- CRISPR Therapeutics
Allogeneic CRISPR-edited CD19 CAR-T in autoimmune trials
- Allogene Therapeutics
Allogeneic CD19/CD70 CAR-T for rheumatology basket
- Century Therapeutics
iPSC-derived CD19 CAR-iNK platform overlap
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Nkarta | $2.90 | +0.69% | $206.1M | — | — | — | — |
| Kyverna Therapeutics | $7.53 | +5.76% | $432.9M | — | — | — | — |
| Cabaletta Bio | $2.52 | +2.24% | $401.1M | — | — | — | — |
| Bristol-Myers Squibb | $62.54 | −0.13% | $127.91B | 13.8 | 9.8 | 2.6 | +5.7% |
| Fate | $2.57 | +1.38% | $294.9M | — | — | 45.4 | +9.2% |
| Sana Biotechnology | $3.17 | +2.13% | $862.7M | — | — | — | — |
| CRISPR Therapeutics | $58.28 | −0.09% | $5.63B | — | — | 420.1 | +1,041.4% |
| Allogene Therapeutics | $1.71 | +0.93% | $583.3M | — | — | 125.7 | — |
| Century Therapeutics | $1.90 | +2.84% | $160.2M | — | — | — | — |
| Median | 13.8 | 9.8 | 85.6 | +9.2% |